Literature DB >> 10397728

Increased fragmentation of von Willebrand factor, due to abnormal cleavage of the subunit, parallels disease activity in recurrent hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and discloses predisposition in families. The Italian Registry of Familial and Recurrent HUS/TTP.

M Galbusera1, M Noris, C Rossi, S Orisio, J Caprioli, Z M Ruggeri, B Amadei, P Ruggenenti, B Vasile, G Casari, G Remuzzi.   

Abstract

We investigated here the changes in von Willebrand factor (vWF) multimers in recurrent, sporadic and familial forms of hemolytic uremic syndrome (HUS)/thrombotic thrombocytopenic purpura (TTP) to see whether they are actually proteolyzed in vivo in these patients. Molecular determinants of fragments in vWF were also characterized to identify possible sites of cleavage of the subunit. Unusually large vWF multimers were found in blood of 8 of 10 patients with recurrent HUS/TTP, both in the acute phase and in remission, but never in familial and sporadic cases. Instead, all of the groups showed evidence of enhanced fragmentation of vWF multimers during the acute phase. Increased fragmentation was also shown by decrease in native 225-kD vWF subunit. In recurrent and sporadic HUS/TTP, enhanced fragmentation normalized at remission, but the abnormality persisted in familial HUS/TTP patients. The latter findings suggest that patients with familial HUS/TTP may have a congenital abnormality in vWF processing. Analysis with specific monoclonal antibodies showed the presence of the normal vWF fragments with apparent molecular mass of 189, 176, and 140 kD in all patients; however, in 6 recurrent and in 5 familial cases, novel fragments that differed in size from normal ones were found. The size of these abnormal fragments differed from one patient to another and none of them was ever found in normal plasma. These results documented, for the first time in HUS/TTP, an abnormal cleavage of the vWF subunit that might account for the increased fragmentation observed in these patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10397728

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

Review 1.  Drug-induced thrombotic microangiopathy: incidence, prevention and management.

Authors:  R Pisoni; P Ruggenenti; G Remuzzi
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

Review 2.  Laboratory testing for von Willebrand disease: toward a mechanism-based classification.

Authors:  Richard Torres; Yuri Fedoriw
Journal:  Clin Lab Med       Date:  2009-06       Impact factor: 1.935

3.  Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype.

Authors:  Elena Bresin; Erica Rurali; Jessica Caprioli; Pilar Sanchez-Corral; Veronique Fremeaux-Bacchi; Santiago Rodriguez de Cordoba; Sheila Pinto; Timothy H J Goodship; Marta Alberti; David Ribes; Elisabetta Valoti; Giuseppe Remuzzi; Marina Noris
Journal:  J Am Soc Nephrol       Date:  2013-02-21       Impact factor: 10.121

4.  Thrombotic microangiopathies: First report of 294 cases from a single institution experience in Argentina.

Authors:  Célia Dos Santos; Juvenal Paiva; María Lucila Romero; Mara Agazzoni; Ana Catalina Kempfer; Sabrina Rotondo; María Marta Casinelli; María Fabiana Alberto; Analía Sánchez-Luceros
Journal:  EJHaem       Date:  2021-01-19

5.  Leukocyte proteases cleave von Willebrand factor at or near the ADAMTS13 cleavage site.

Authors:  Thomas J Raife; Wenjing Cao; Bonnie S Atkinson; Bruce Bedell; Robert R Montgomery; Steven R Lentz; George F Johnson; X Long Zheng
Journal:  Blood       Date:  2009-06-18       Impact factor: 22.113

6.  ADAMTS13 Secretion and Residual Activity among Patients with Congenital Thrombotic Thrombocytopenic Purpura with and without Renal Impairment.

Authors:  Erica Rurali; Federica Banterla; Roberta Donadelli; Elena Bresin; Miriam Galbusera; Sara Gastoldi; Flora Peyvandi; Mary Underwood; Giuseppe Remuzzi; Marina Noris
Journal:  Clin J Am Soc Nephrol       Date:  2015-09-04       Impact factor: 8.237

7.  A non-invasive laboratory panel as a diagnostic and prognostic biomarker for thrombotic microangiopathy: development and application in a Chinese cohort study.

Authors:  Tao Zhang; Huimei Chen; Shaoshan Liang; Dacheng Chen; Chunxia Zheng; Caihong Zeng; Haitao Zhang; Zhihong Liu
Journal:  PLoS One       Date:  2014-11-05       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.